UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC) Meeting Abstract
| Authors: | Hays, J. L.; Friedman, C. F.; Lakhani, N.; Anderson, C. K.; Buscema, J.; Duska, L. R.; Hamilton, E. P.; Taylor, S. E.; Carrington, C.; Burger, R. A.; Werner, T. L. |
| Abstract Title: | UPGRADE-A: Phase 1 expansion trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi) in combination with carboplatin in patients with high-grade serous ovarian cancer (HGSOC) |
| Meeting Title: | 2023 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2023 Jun 2-6 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Language: | English |
| DOI: | 10.1200/JCO.2023.41.16_suppl.TPS5613 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting Abstract: TPS5613 -- Meeting was also available virtually -- Source: Cinahl |
